April 2023 in “JMIR Research Protocols” The study aims to create a model to predict health attributes using diverse health data from Japanese adults.
IVL-DrugFluidic® can mass-produce high-quality, long-acting injectable drug microspheres, improving patient compliance and reducing side effects.
March 2023 in “Anais Brasileiros De Dermatologia” The document reviews various treatments for female pattern hair loss (FPHL), highlighting the efficacy and safety of different therapeutic options. Topical minoxidil is the most supported treatment but is ineffective for about 40% of patients. Oral minoxidil shows promise but has potential side effects. Antiandrogens like spironolactone and bicalutamide are effective in certain cases, with cyproterone being more effective in hyperandrogenism. Emerging treatments like microneedling, platelet-rich plasma (PRP) therapy, and low-level laser therapy (LLLT) show potential but require more research. The review emphasizes the need for personalized treatment plans and further randomized clinical trials to improve FPHL management.
January 2023 in “Pharmaceutics” December 2022 in “Frontiers in Microbiology” 52 citations,
June 1981 in “International Journal of Dermatology” Oral retinoids are effective for severe skin conditions but require careful use due to side effects.
2 citations,
January 2018 in “Elsevier eBooks” Lipid nanoparticles improve drug delivery through the skin, offering stability, controlled release, and better compatibility with skin.
8 citations,
April 1965 in “Archives of biochemistry and biophysics” Sheep wool follicles can metabolize both glucose and acetate using different pathways important for wool growth.
1 citations,
May 2022 in “Research Square (Research Square)” Acetate helps reduce depression in rats with PCOS by lowering specific gene expression and DNA changes in the brain.
232 citations,
June 1975 in “Journal of Steroid Biochemistry” Cyproterone acetate is effective for acne but less so for hirsutism and alopecia, with some side effects and quick menstrual cycle recovery after treatment.
149 citations,
June 2002 in “British Journal of Dermatology” Minoxidil works better for female hair loss, but cyproterone reduces scalp oiliness and causes menstrual issues.
129 citations,
January 1977 in “Hormone and metabolic research” Cyproterone Acetate effectively treats androgen-related conditions and is used in prostate cancer therapy and hormone therapy for transgender women.
113 citations,
April 1999 in “The Journal of Clinical Endocrinology and Metabolism” Cyproterone acetate-estrogen most effective for hirsutism, but consider side effects and patient needs.
94 citations,
July 1991 in “Clinical endocrinology” Cyproterone acetate at 2mg daily is as effective as higher doses for treating excessive hair growth in women.
88 citations,
November 2011 in “British Journal of Clinical Pharmacology” High doses of cyproterone acetate are linked to an increased risk of developing meningioma.
83 citations,
April 1992 in “Clinical Endocrinology” Having enough iron improves the effectiveness of a specific hair loss treatment in women.
78 citations,
October 2003 in “Cochrane library” Cyproterone acetate with estradiol may subjectively improve excessive hair growth in women, but it's not clinically better than other treatments.
74 citations,
April 2002 in “PubMed” Both oral contraceptives reduced acne effectively and had similar positive effects on skin oiliness and hair growth.
68 citations,
May 1991 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Both cyproterone acetate and spironolactone effectively reduce hair growth in women with hirsutism.
66 citations,
October 1977 in “British journal of dermatology/British journal of dermatology, Supplement” Cyproterone acetate reduces hair growth and oil production.
64 citations,
March 1984 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Cyproterone acetate effectively reduced hair growth in hirsute patients by lowering androgen levels and altering androgen metabolism.
59 citations,
February 2021 in “BMJ” High doses of cyproterone acetate increase the risk of brain tumors in women, but the risk decreases after stopping the medication.
58 citations,
July 1974 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Cyproterone acetate combined with ethinyl estradiol significantly reduced hirsutism in women.
56 citations,
April 2003 in “Fertility and Sterility” All three treatments reduce hirsutism, but spironolactone works best long-term.
52 citations,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
49 citations,
June 1998 in “Journal of Endocrinological Investigation” Cyproterone acetate plus ethinyl estradiol is generally more effective in treating hirsutism, but consider side effects and patient characteristics.
49 citations,
April 1997 in “Human reproduction” Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.
49 citations,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” The combination of cyproterone acetate and testosterone enanthate is highly effective in preventing sperm production and could be a good reversible male contraceptive.
43 citations,
May 1986 in “Clinics in Endocrinology and Metabolism” Cyproterone acetate is effective for treating hirsutism and acne but less so for hair loss, with side effects similar to birth control pills.